Bayesian methods for the design and analysis of noninferiority trials

被引:16
|
作者
Gamalo-Siebers, Margaret [1 ]
Gao, Aijun [2 ]
Lakshminarayanan, Mani [3 ]
Liu, Guanghan [4 ]
Natanegara, Fanni [5 ]
Railkar, Radha [3 ]
Schmidli, Heinz [6 ]
Song, Guochen [7 ]
机构
[1] US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD USA
[2] InVent Hlth Clin, Princeton, NJ USA
[3] Pfizer Inc, Biotechnol Clin Dev Stat, Collegeville, PA 19426 USA
[4] Merck Sharp & Dohme Corp, N Wales, PA USA
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Novartis Pharma AG, Basel, Switzerland
[7] Quintiles, Durham, NC USA
关键词
Bayesian inference; clinical trial; meta-analysis; noninferiority; ACTIVE-CONTROL TRIALS; SAMPLE-SIZE CALCULATIONS; NON-INFERIORITY TRIALS; CLINICAL-TRIALS; HISTORICAL INFORMATION; STATISTICAL-METHODS; PLACEBO; PROPORTIONS; COMBINATION; HYPOTHESIS;
D O I
10.1080/10543406.2015.1074920
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The gold standard for evaluating treatment efficacy of a medical product is a placebo-controlled trial. However, when the use of placebo is considered to be unethical or impractical, a viable alternative for evaluating treatment efficacy is through a noninferiority (NI) study where a test treatment is compared to an active control treatment. The minimal objective of such a study is to determine whether the test treatment is superior to placebo. An assumption is made that if the active control treatment remains efficacious, as was observed when it was compared against placebo, then a test treatment that has comparable efficacy with the active control, within a certain range, must also be superior to placebo. Because of this assumption, the design, implementation, and analysis of NI trials present challenges for sponsors and regulators. In designing and analyzing NI trials, substantial historical data are often required on the active control treatment and placebo. Bayesian approaches provide a natural framework for synthesizing the historical data in the form of prior distributions that can effectively be used in design and analysis of a NI clinical trial. Despite a flurry of recent research activities in the area of Bayesian approaches in medical product development, there are still substantial gaps in recognition and acceptance of Bayesian approaches in NI trial design and analysis. The Bayesian Scientific Working Group of the Drug Information Association provides a coordinated effort to target the education and implementation issues on Bayesian approaches for NI trials. In this article, we provide a review of both frequentist and Bayesian approaches in NI trials, and elaborate on the implementation for two common Bayesian methods including hierarchical prior method and meta-analytic-predictive approach. Simulations are conducted to investigate the properties of the Bayesian methods, and some real clinical trial examples are presented for illustration.
引用
下载
收藏
页码:823 / 841
页数:19
相关论文
共 50 条
  • [21] Bayesian methods for analysis of biosimilar phase III trials
    Weiss, Robert E.
    Xia, Xiaomao
    Zhang, Nan
    Wang, Hui
    Chi, Eric
    STATISTICS IN MEDICINE, 2018, 37 (20) : 2938 - 2953
  • [22] Assessment of Noninferiority (and Equivalence) for Simple Crossover Trials Using Bayesian Approach
    Yang M.
    Statistics in Biosciences, 2018, 10 (3) : 506 - 519
  • [23] Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies
    O'Hagan, A
    Stevens, JW
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2002, 11 (06) : 469 - 490
  • [24] Noninferiority Trials
    Lange, Stefan
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (03): : 303 - 303
  • [25] Noninferiority Trials
    Mitka, Mike
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (14): : 1546 - 1546
  • [26] Noninferiority trials
    Steven M Snapinn
    Trials, 1 (1)
  • [27] Noninferiority is (too) common in noninferiority trials
    Soonawala, Darius
    Dekkers, Olaf M.
    Vandenbroucke, Jan P.
    Egger, Matthias
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2016, 71 : 118 - 120
  • [28] Design of HIV noninferiority trials: where are we going?
    Flandre, Philippe
    AIDS, 2013, 27 (04) : 653 - 657
  • [29] Some current issues in the design of HIV noninferiority trials
    Flandre, Philippe
    AIDS, 2014, 28 (13) : 1921 - 1929
  • [30] Bayesian design and analysis of active control clinical trials
    Simon, R
    BIOMETRICS, 1999, 55 (02) : 484 - 487